Ralliant (NYSE:RAL) Updates Q2 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its second quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.580-0.640 for the period, compared to the consensus EPS estimate of 0.520. The company issued revenue guidance of $540.0 million-$556.0 million, compared to the consensus revenue estimate of $529.0 million. Ralliant also updated its FY 2026 guidance to 2.530-2.690 EPS.

Ralliant Trading Up 19.3%

RAL stock opened at $59.13 on Wednesday. The business has a fifty day moving average price of $44.59 and a 200 day moving average price of $47.19. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 0.58. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $60.14. The stock has a market capitalization of $6.62 billion and a price-to-earnings ratio of 30.17.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts expect that Ralliant will post 2.37 EPS for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio is 10.20%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on RAL shares. Royal Bank Of Canada decreased their price objective on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 6th. Barclays reiterated an “overweight” rating and set a $67.00 target price on shares of Ralliant in a research report on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Friday, February 6th. Finally, Truist Financial reduced their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.

Insider Buying and Selling

In related news, SVP Karen M. Bick sold 2,530 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $46.50, for a total value of $117,645.00. Following the completion of the sale, the senior vice president owned 42,652 shares in the company, valued at approximately $1,983,318. This represents a 5.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Hedge Funds Weigh In On Ralliant

Institutional investors have recently modified their holdings of the stock. Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the 3rd quarter valued at approximately $26,000. BOKF NA acquired a new position in Ralliant during the third quarter valued at approximately $29,000. Wilmington Savings Fund Society FSB acquired a new position in Ralliant during the third quarter valued at approximately $30,000. EverSource Wealth Advisors LLC bought a new stake in Ralliant in the second quarter valued at approximately $39,000. Finally, NewEdge Advisors LLC bought a new stake in Ralliant in the second quarter valued at approximately $43,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.